BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
10 janv. 2023 07h15 HE
|
BioNTech SE
Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by leveraging artificial intelligence and...
BioNTech kündigt strategische Partnerschaft mit der Regierung des Vereinigten Königreichs an, um bis 2030 bis zu 10.000 Patientinnen und Patienten mit personalisierten mRNA-Krebsimmuntherapien zu behandeln
05 janv. 2023 19h01 HE
|
BioNTech SE
Die mehrjährige Vereinbarung fokussiert sich auf drei strategische Bereiche: Krebsimmuntherapien, Impfstoffe gegen Infektionskrankheiten und weitere Expansion von BioNTech im Vereinigten...
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
05 janv. 2023 19h01 HE
|
BioNTech SE
Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech’s footprint in the UKBioNTech aims to design and roll out...
BiondVax Announces Closing of $8 Million Underwritten Public Offering
20 déc. 2022 12h42 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)(“Company”), a biotechnology company, which focuses on developing, manufacturing, and...
Infectious Disease Diagnostics Market Size & Share to Surpass $ 41,291.40 Mn by 2028 | Vantage Market Research
16 déc. 2022 03h41 HE
|
Vantage Market Research
WASHINGTON, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research analyses that the Global Infectious Disease Diagnostics Market is expected to reach a value of $ 41,291.40 Million by 2028, at a...
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
06 déc. 2022 07h30 HE
|
BiondVax Pharmaceuticals Ltd.
Jerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing...
Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
05 déc. 2022 06h30 HE
|
Veru Inc.
U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS European Medicines Agency’s (EMA) Emergency Task Force reviewing sabizabulin for...
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19
30 nov. 2022 15h01 HE
|
POP Biotechnologies
BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2...
PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress
21 nov. 2022 08h00 HE
|
PDS Biotechnology Corporation
Chief Medical Officer, Dr. Lauren V. Wood, to present on the development of targeted immunotherapies for solid tumors based on the Versamune® platform Dr. Siva Gandhapudi, Director of...
BiondVax Announces Plan to Implement ADS Ratio Change
10 nov. 2022 16h00 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...